黄连素治疗慢性萎缩性胃炎的临床疗效及对患者血清VEGF、PGⅠ、PGⅡ水平的影响

Curative Efficacy of Berberine in the Treatment of Chronic Atrophic Gastritis and Effect on the Serum VEGF, PGⅠ, PGⅡ Levels

目的:探讨黄连素治疗慢性萎缩性胃炎的临床疗效及对患者血清血管内皮生长因子(VEGF)、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)水平及胃蛋白酶原Ⅰ/胃蛋白酶原Ⅱ(PGR)的影响。方法:选择2015年1月至2017年1月我院接诊的96例慢性萎缩性胃炎患者,随机分为观察组(n=48)和对照组(n=48)。对照组进行常规治疗,胃幽门螺旋杆菌(Hp)阴性的患者口服奥美拉唑肠溶胶囊,Hp阳性的患者口服阿莫西林胶囊+克拉霉素胶囊+奥美拉唑肠溶胶囊,观察组联合复方黄连素片治疗。比较两组治疗前后血清VEGF、PGⅠ、PGⅡ、PGR、Hp阳性率的变化、临床疗效及不良反应的发生情况。结果:治疗后,两组血清VEGF、PGⅠ、PGR水平以及Hp阳性率均较治疗前明显改善(P<0.05),PGⅡ较治疗前均未有显著改变(P>0.05);且观察组血清VEGF水平、Hp阳性率明显低于对照组(P<0.05),血清PGⅠ、PGR水平明显高于对照组(P<0.05);观察组临床疗效总有效率明显高于对照组(P<0.05)。两组治疗期间均未有恶心呕吐、白细胞减少、肝肾功能异常等严重不良反应。结论:黄连素可显著提高慢性萎缩性胃炎患者的临床效果,其作用机制可能和改善患者血清VEGF、PGⅠ、PGⅡ水平有关。

Objective： To study the curative efficacy of berberine in the treatment of chronic atrophic gastritis and effect on the serum VEGF, PG I, PG lI and PG I / PG II （PGR） levels. Methods： 96 patients of chronic atrophic gastritis who were treated from Jan- uary 2015 to January 2017 in our hospital were selected and divided into the observation group （n=48） and the control group （n=48） ac- cording to random number table. The control group was treated with routine treatment, the Gastric Helicobacter pylori infection （Hp） negative patients were treated with oral omeprazole enteric-coated capsules, Hp positive patients were treated with oral amoxicillin cap- sules, clarithromycin capsules and omeprazole enteric-coated capsules, while the observation group was combined with compound berberine tablets. The changes of serum VEGF, PG I , PG II, PGR and Hp positive rate before and after treatment, clinical efficacy and the incidence of adverse reactions were compared between two groups. Results： After treatment, the serum VEGF, PG I , PGR and Hp positive rate of both groups were all significantly improved compared with those before treatment （P 〈0.05）, there was no significant change in the serum PG II level before and after treatment in the two groups （P 〉0.05）; the serum VEGF of observation group was signifi- cantly lower than that of the control group （P〈0.05）; the serum PG I, PGR of observation group were significantly higher than those of the control group（P 〈0.05）; the Hp positive rate of observation group were significantly lower than those of the control group（P 〈 0.05）; the total effective rate of observation group was significantly higher than that of the control group （P〈0.05）; there was no severe adverse reactions such as nau- sea, vomiting, white blood cell, and abnormal liver and kidney function in two groups. Conclusion： Compound berberine tablets can effectively enhance the clinical efficacy of chronic atrophic gastritis, which may be related to improvethe serum levels ofVEGF, PG I, PG.